As FXR, pregnane X receptor (PXR), and CAR ligands regulate different target genes, it seems that a combination of ligands/activators of FXR, PXR, and/or CAR could reduce the potential side effects of FXR activation alone in severe cholestasis [31]. This evidence concerns the gene NR1I2 and cholestasis.